MiMedx Group, Inc. provided earnings guidance for the full year 2022. For the year, the company expects net sales of its continuing portfolio of products, which were $240.0 million in 2021, to grow 11% to 14% in 2022.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.11 USD | -0.56% | -3.73% | -17.56% |
Apr. 30 | Transcript : MiMedx Group, Inc., Q1 2024 Earnings Call, Apr 30, 2024 | |
Apr. 30 | Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 Revenue $84.7M, vs. Street Est of $79.4M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.56% | 1.06B | |
-25.27% | 120M | |
-13.07% | 64.19M | |
-5.39% | 52.84M | |
-6.87% | 50.21M |
- Stock Market
- Equities
- MDXG Stock
- News MiMedx Group, Inc.
- MiMedx Group, Inc. Provides Earnings Guidance for the Full Year 2022